GlaxoSmithKline News and Research

RSS

Denator forms a new Scientific Advisory Board

Denator AB has announced that a new external expert advisory board has been formed. Karsten Fjärstedt, recently appointed as CEO comments, “It is a great honor for me to be entrusted to lead Denator forward in this new phase of development. With a pipeline of new exciting business opportunities and a strong Scientific Advisory Board (SAB) I am looking forward to realizing the full potential of the company technology”.

3 Nov 2015

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

Researchers use cutting edge genomic methods to explain protective effects of malaria vaccine candidate

An international team led by researchers from the Broad Institute of MIT and Harvard, the Harvard T.H. Chan School of Public Health, and Fred Hutchinson Cancer Research Center have used cutting edge genomic methods to uncover key biological insights that help explain the protective effects of the world's most advanced malaria vaccine candidate, RTS,S/AS01 (RTS,S).

22 Oct 2015

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.

9 Oct 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

Reducing hospital readmissions through Transitional Care: an interview with Rani Khetarpal

Services provided to a patient whose medical and/or psychosocial problems require moderate or high-complexity medical decision making during transitions in care from an inpatient setting, partial hospital, observation status in a hospital, or skilled nursing facility to the patient’s community setting.

27 Aug 2015

New article proposes creation of $2 billion global vaccine-development fund to prevent infectious diseases

Ebola is a preventable disease, and yet a safe and effective vaccine has not been deployed. As with many vaccines, financial barriers persist: pharmaceutical companies see high costs with limited market potential, and government support is lacking. But there may be a solution to this vaccine crisis with the ability to save at-risk populations, according to a perspective piece written by physicians based at Princeton University, University of Pennsylvania and the Wellcome Trust.

4 Aug 2015

New white paper provides overview of factors that drive vaccination underutilization in older adults

Today the nonprofit Alliance for Aging Research released a white paper, Our Best Shot: Expanding Prevention through Vaccination in Older Adults, that provides a comprehensive overview of the factors that drive vaccination underutilization in seniors and offers recommendations on how industry, government, and health care experts can improve patient compliance.

30 Jul 2015

New consortium aims to develop precision medicines for globally devastating diseases

An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.

29 Jul 2015

United Therapeutics’ revenues increase by $24.4 million in second quarter 2015

United Therapeutics Corporation today announced its financial results for the second quarter ended June 30, 2015. "Orenitram sales grew nearly 300% as compared to the second quarter of 2014 when the product was first launched," said Roger Jeffs, Ph.D., United Therapeutics' President and Co-Chief Executive Officer.

28 Jul 2015

Perrigo signs agreement to acquire Naturwohl Pharma

Perrigo Company plc today announced that it has entered into an agreement to acquire Naturwohl Pharma GmbH with its leading German dietary supplement brand, Yokebe. The brand is expected to generate approximately €30 million in full year 2015 net sales.

22 Jul 2015

Ebola vaccine study begins in Dakar, Senegal

A trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial immunisations started at the Jenner Institute, Oxford University. The announcement comes as a conference in Oxford discusses the global response to Ebola and the implications for future drug and vaccine development.

15 Jul 2015

GSK welcomes U.S. CDC's vote on use of meningococcal group B vaccines

GlaxoSmithKline announced today that the U.S. Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) voted for a Category B recommendation for meningococcal group B vaccination, including BEXSERO (Meningococcal Group B Vaccine), in individuals aged 16 to 23 (with a preferred age of 16-18).

25 Jun 2015

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022" the Heparin Market Europe was valued at USD 2,004.5 million in 2013 and is estimated to reach USD 3,148.0 million by 2022 growing with a CAGR of 5.2% from 2014 to 2022.

17 Jun 2015

No added benefit with pazopanib over ranibizumab for neovascular AMD

Pazopanib eye drops do not enhance visual outcomes in patients with neovascular age-related macular degeneration beyond those achieved with ranibizumab alone, study findings indicate.

19 May 2015

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).

19 May 2015

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

A new vaccine has proven almost completely effective in preventing shingles (disease medical name: herpes zoster), an extremely painful nerve infection which affects a third of Australians; most over the age of 50...

13 May 2015

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

1 May 2015

Two experimental Ebola vaccines appear to be safe in PREVAIL clinical trial in Liberia

Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase 2/3 clinical trial, according to interim findings from an independent Data and Safety Monitoring Board review.

30 Mar 2015

Study: Cancer drug may help reduce bleeding in HHT patients

A cancer drug that helps keep tumors from growing blood vessels may help patients with a rare genetic condition in which malformed vessels increase their risk for bleeding and anemia.

17 Mar 2015

GlaxoSmithKline News and Research

Denator forms a new Scientific Advisory Board

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Researchers use cutting edge genomic methods to explain protective effects of malaria vaccine candidate

Manchester researchers demonstrate safety, effectiveness of eltrombopag treatment in children with ITP

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Reducing hospital readmissions through Transitional Care: an interview with Rani Khetarpal

New article proposes creation of $2 billion global vaccine-development fund to prevent infectious diseases

New white paper provides overview of factors that drive vaccination underutilization in older adults

New consortium aims to develop precision medicines for globally devastating diseases

United Therapeutics’ revenues increase by $24.4 million in second quarter 2015

Perrigo signs agreement to acquire Naturwohl Pharma

Ebola vaccine study begins in Dakar, Senegal

GSK welcomes U.S. CDC's vote on use of meningococcal group B vaccines

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

No added benefit with pazopanib over ranibizumab for neovascular AMD

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

New approach to vaccine development is 97 per cent efficacious and could eliminate shingles

Two experimental Ebola vaccines appear to be safe in PREVAIL clinical trial in Liberia

Study: Cancer drug may help reduce bleeding in HHT patients

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News